	US 11,685,784 B2
	Anti-immune-checkpoint nanobody and nucleic acid encoding sequence thereof, and uses of the same
Der-Yang Cho, Taichung (TW); Shao-Chih Chiu, Taichung (TW); Shi-Wei Huang, Taichung (TW); Chih-Ming Pan, Taichung (TW); Mei-Chih Chen, Taichung (TW); Yu-Chuan Lin, Taichung (TW); and Yeh Chen, Taichung (TW)
Assigned to CHINA MEDICAL UNIVERSITY HOSPITAL, Taichung (TW)
Filed by China Medical University Hospital, Taichung (TW)
Filed on Mar. 11, 2022, as Appl. No. 17/692,701.
Claims priority of provisional application 63/165,274, filed on Mar. 24, 2021.
Prior Publication US 2022/0306746 A1, Sep. 29, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2827 (2013.01) [C07K 16/2818 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/92 (2013.01)]

19 Claims

1. An anti-immune-checkpoint nanobody that specifically binds to a programmed cell death ligand 1 (PD-L1), consisted of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 3; wherein the anti-immune-checkpoint nanobody is produced and purified from Escherichia coli (E. coli) strain HB2151.